According to the research report titled ‘Global Preimplantation Genetic Testing Market Size study, By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Single Nucleotide Polymorphism (SNP)), By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification), By End User (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes), and Regional Forecasts 2022-2028’, available with MarketStudyReport, global preimplantation genetic testing market accounted for USD 492.53 million in 2021 and is anticipated to reach USD 959.79 million 2028, registering a 10% CAGR during the analysis timeframe.

The increasing number of fertility clinics, technological advancements, and the growing public-private investments are some of the primary factors driving the expansion of global preimplantation genetic testing market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/5065459/  

For those unaware, pre-implantation genetic testing is used for the genetic analysis of embryos before implantation to identify genetically imbalanced structures in newborns and children. Aside from this, the declining fertility rate, growing awareness regarding assisted reproduction techniques, the rising incidences of chromosomal abnormalities, and increasing medical tourism are impelling the overall market growth.

However, the high procedural cost and unfavorable government regulations are likely to hinder the growth of global preimplantation genetic testing industry over the forecast period.

Based on product and services, the market is divided into software & services, instruments, and reagents & consumables. Moving on to the technology type, the industry is fragmented into single nucleotide polymorphism, comparative genomic hybridization, fluorescent in-situ hybridization, polymerase chain reaction, and next-generation sequencing.

As per procedure type, the market is split into preimplantation genetic diagnosis and preimplantation genetic screening. In terms of the application landscape, the industry is classified into gender identification, linked disorders, single-gene disorders, HLA typing, X structural chromosomal abnormalities, and aneuploidy segments.

With respect to the end-user spectrum, the market is categorized into research laboratories & academic institutes, hospitals, diagnostic labs & service providers, and maternity centers & fertility clinics.

Regionally, North America is expected to hold the largest share in global preimplantation genetic testing industry during the forecast timeframe, owing to the rising demand for genomic techniques and the growing utilization of IVF procedures.

Whereas Asia-Pacific market is projected to record a healthy CAGR over the study period, on account of rising developments in healthcare infrastructure and the growing focus of leading players in emerging economies.

Yikon Genomics Co. Ltd., Good Start Genetics Inc., Natera Inc., Abbott Laboratories Inc., BGI Group, CooperSurgical Inc., PerkinElmer Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Illumina Inc. are the prominent players operating in global preimplantation genetic testing industry.